Aspira Women's Health (AWH) Investor presentation summary

Transforming gynecologic care with AI-powered diagnostics

• Focus on revolutionizing women's health through innovative, data-driven testing options for optimal gynecologic care.

• Leveraging artificial intelligence and multi-omic technology to enhance risk assessment and clinical utility.

Addressable market and product pipeline

• Combined market potential exceeds 10.5 million patients, including ovarian cancer and endometriosis diagnostics.

• OvaSuite and ENDOinform target large populations with unmet diagnostic needs.

• Pipeline includes next-generation AI-powered blood tests for ovarian cancer and endometriosis.

Ovarian cancer diagnostics and clinical impact

• Ova1 Plus and OvaWatch offer high sensitivity and negative predictive value for ovarian cancer risk assessment.

• Ova1 detects 63% of early-stage malignancies missed by CA-125, with improved detection in both pre- and post-menopausal women.

• OvaWatch could reduce avoidable adnexal mass surgeries by up to 62%.